Jan 22, 2025 · Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions.

leave axsome.com. You will now be sent to a website that is not controlled or owned by Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for the website you are about to go to, which may not be appropriate for everyone.

Get information on Axsome products that are currently in-market, developed to find new ways to solve treatment gaps in CNS conditions.

AXS-05 (dextromethorphan-bupropion) is a novel, oral, NMDA receptor antagonist being developed for the treatment of multiple CNS conditions. Learn more and see clinical and regulatory information.

View a list of current career opportunities at Axsome Therapeutics and submit an application.

Learn more about the conditions we focus on and the work Axsome is doing to bring meaningful changes for patients with CNS conditions.

Migraine is common and debilitating, affecting over 37 million Americans. Learn about Axsome's work in migraine, key facts and the unmet needs of patients.

Axsome data on file. CTAD 2020 Digital Conference, November 4 -7, 2020. AXS-05: Novel, Oral, NMDA Receptor Antagonist with Multimodal Activity

See how you can contact Axsome Therapeutics by phone, email, or standard mail or submit a contact request.